BIOMAT Database Logo BIOMAT Database Logo

Activity of the combination of nelfinavir and saquinavir against human immunodeficiency virus after failure of prior protease inhibitor therapy. 1999

S Kravcik, and G Victor, and J B Angel, and A D Badley, and G E Garber, and D W Cameron
Division of General Medicine, Ottawa Hospital, University of Ottawa, Ontario, Canada. skravcik@ogh.on.ca

UI MeSH Term Description Entries
D008297 Male Males
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016879 Salvage Therapy A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases. Salvage Treatment,Therapy, Salvage,Salvage Therapies,Salvage Treatments,Therapies, Salvage,Treatment, Salvage,Treatments, Salvage
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017211 Treatment Failure A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series. Failure, Treatment,Failures, Treatment,Treatment Failures

Related Publications

S Kravcik, and G Victor, and J B Angel, and A D Badley, and G E Garber, and D W Cameron
Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
February 2000, European journal of medical research,
S Kravcik, and G Victor, and J B Angel, and A D Badley, and G E Garber, and D W Cameron
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.
April 2001, Journal of acquired immune deficiency syndromes (1999),
S Kravcik, and G Victor, and J B Angel, and A D Badley, and G E Garber, and D W Cameron
Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.
January 2001, HIV clinical trials,
S Kravcik, and G Victor, and J B Angel, and A D Badley, and G E Garber, and D W Cameron
Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.
May 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
S Kravcik, and G Victor, and J B Angel, and A D Badley, and G E Garber, and D W Cameron
Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
October 1997, Antimicrobial agents and chemotherapy,
S Kravcik, and G Victor, and J B Angel, and A D Badley, and G E Garber, and D W Cameron
Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats.
February 2009, Biological & pharmaceutical bulletin,
S Kravcik, and G Victor, and J B Angel, and A D Badley, and G E Garber, and D W Cameron
Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
November 2003, Biopharmaceutics & drug disposition,
S Kravcik, and G Victor, and J B Angel, and A D Badley, and G E Garber, and D W Cameron
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
December 2001, Antimicrobial agents and chemotherapy,
S Kravcik, and G Victor, and J B Angel, and A D Badley, and G E Garber, and D W Cameron
Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.
July 1998, Drug metabolism and disposition: the biological fate of chemicals,
S Kravcik, and G Victor, and J B Angel, and A D Badley, and G E Garber, and D W Cameron
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
June 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!